Report blames gaming of patent system for high drug prices
Most drugs named are biologics, and manufacturing trade secrets make competition especially tricky, legal expert says.
Most drugs named are biologics, and manufacturing trade secrets make competition especially tricky, legal expert says.
Nevertheless, the proposed policy could take Martin Shkreli-like practices "out of the ballgame," expert says.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The administration also quietly pulled out of its widely publicized pay-for-performance program for Novartis' CAR-T Kymriah.
Despite the Trump administration's moves that appear to undermine value-based care, a closer look shows the reality is a bit more complicated.
Will Health and Human Services Secretary Alex Azar use his authority to compel Idaho to follow the ACA and reject the Blues plans?
In a 55-43 vote, the Senate has confirmed Alex Azar as the new secretary of the Department of Health and Human Services. President Donald Trump nominated Azar in November following the resignation of Tom Price.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Senate Democrats on Tuesday pressed President Donald Trump’s nominee for the top health post to explain how he would fight skyrocketing drug prices. Alex Azar is the former president of the U.S. division of Eli Lilly and Trump’s pick to run the Department of Health and Human Services,
As different strategies to address the drug-pricing crisis are discussed and considered, it is worth remembering that HHS already has the power necessary to reduce the costs for many patented, life-saving medicines through a provision of the Bayh-Dole Act of 1980.
As HHS secretary, Alex Azar would oversee a trillion-dollar budget, over 90,000 employees, and a healthcare system that is ground-zero for heated bipartisan politics. So where does Trump’s new nominee stand on the major issues?
Alex Azar also has some particularly relevant experience as deputy Health and Human Services Secretary under George W. Bush, but will his pharma background put off a president who has been critical of the drug industry's pricing practices?